Biotechnology company CytoDyn Inc. (OTCQB: CYDY) is the
focus of a recently-released corporate summary from leading independent small
cap media portal EmergingGrowth.com. The update details a number of topics from
CytoDyn’s recent shareholder conference call, including highlights from the
ongoing clinical development of its PRO 140 viral-entry inhibitor. The
EmergingGrowth.com report notes that PRO 140 demonstrated a 93 percent
suppression rate in 525mg trials after a six-week induction period. The summary
further details CytoDyn’s new monotherapy trial, as well as the company’s
recent efforts to generate capital through the sale of shares and the
exploration of non-dilutive licensing pathways, particularly as they pertain to
the company’s August acquisition of Prostagene and related licensing rights for
“an extremely accurate prostate cancer prognostic that the competitor sells for
$3,000.”
To view the full press release, visit http://ibn.fm/uDNQC
About CytoDyn
CytoDyn is a biotechnology company focused on the clinical
development and potential commercialization of humanized monoclonal antibodies
for the treatment and prevention of HIV infection. The Company has one of the
leading monoclonal antibodies under development for HIV infection, PRO 140,
which has completed Phase 2 clinical trials with demonstrated antiviral
activity in humans and is currently in Phase 3 development. PRO 140 blocks the
HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial
results thus far indicate that PRO 140 does not negatively affect the normal
immune functions that are mediated by CCR5. Results from seven Phase 1 and
Phase 2 human clinical trials have shown that PRO 140 can significantly reduce
viral burden in people infected with HIV. A recent Phase 2b clinical trial
demonstrated that PRO 140 can prevent viral escape in patients during several
months of interruption from conventional drug therapy. CytoDyn intends to
continue to develop PRO 140 as a therapeutic anti-viral agent in persons
infected with HIV and to pursue non-HIV, inflammatory indications where CCR5
and its ligand CCL5 may be involved. For more information, visit the company’s
website at www.CytoDyn.com
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment